 
                    
                ALLERGY THERAPEUTICS PLC
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
AGY | IL
Overview
Corporate Details
- ISIN(s):
- GB00B02LCQ05
- LEI:
- 213800PQ7AHK7KGVOE23
- Country:
- United Kingdom
- Address:
- DOMINION WAY, BN14 8SA WORTHING
- Website:
- https://allergytherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Allergy Therapeutics PLC is an international, commercial-stage biotechnology company focused on the treatment and diagnosis of allergic disorders. Leveraging its specialist expertise in immunology, the company researches and develops a portfolio of convenient allergy immunotherapy (AIT) products. A key area of focus is its innovative, aluminum-free vaccines that have the potential to modify or cure allergic diseases. The company markets its products primarily across Europe, aiming to transform the lives of patients by providing effective and convenient treatments for various allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-29 08:00 | Share Issue/Capital Change Warrant Exercise and Paydown of Debt  | English | 42.4 KB | ||
| 2025-10-16 08:00 | Regulatory News Service Further progress in Phase I/IIa PROTECT trial | English | 18.4 KB | ||
| 2025-07-31 08:00 | Report Publication Announcement Grass MATA MPL Publications in Allergy Journal | English | 19.2 KB | ||
| 2025-07-21 08:00 | Business and Financial Review Trading update for the year ended 30 June 2025 | English | 19.9 KB | ||
| 2025-07-11 08:00 | Share Issue/Capital Change PDMR Dealings | English | 38.3 KB | ||
| 2025-03-31 08:00 | Interim Report Interim Results for six months ended 31 Dec 2024 | English | 211.9 KB | ||
| 2025-03-27 08:00 | Legal Proceedings Report Advancement to final phase of PROTECT trial | English | 16.8 KB | ||
| 2025-03-03 08:00 | Remuneration Information New Executive Long Term Incentive Awards | English | 42.9 KB | ||
| 2025-02-27 08:00 | Regulatory News Service Presentations at 2025 AAAAI / WAO Joint Congress | English | 15.9 KB | ||
| 2025-02-17 08:00 | Environmental & Social Information Grass MATA MPL Phase III data published in Allergy | English | 17.1 KB | ||
| 2025-02-14 08:00 | Remuneration Information Grant of Options   | English | 36.4 KB | ||
| 2025-01-28 08:00 | Earnings Release Half Year Trading update | English | 15.6 KB | ||
| 2025-01-22 08:00 | Share Issue/Capital Change PDMR Dealing and Total Voting Rights  | English | 28.0 KB | ||
| 2025-01-15 08:00 | Director's Dealing Director/PDMR Shareholding | English | 32.6 KB | ||
| 2024-12-19 14:41 | Share Issue/Capital Change Exercise of Options and Total Voting Rights | English | 10.1 KB | 
Automate Your Workflow. Get a real-time feed of all ALLERGY THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALLERGY THERAPEUTICS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALLERGY THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value | 
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
 
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                    